Medcom Tech Operating Cash Flow
Delisted
The Operating Cash Flow of Medcom Tech (MED.MC) as of Jul 26, 2026 is -1.96 M EUR. In the previous year, Operating Cash Flow was 363,754.00 EUR — a change of -639.55% (lower).
Get this data via API
Financial Data API
Operating Cash Flow
-1.96 MEUR
YoY
-639.55%
Last updated:
Operating Cash Flow of Medcom Tech is 2026 -1.96 M EUR. Operating Cash Flow of Medcom Tech was 2025 363,754.00 EUR. It decreases by -639.55% lower compared to the previous year.
Access this data via the Eulerpool API
Medcom Tech Stock analysis
What does Medcom Tech do? Medcom Tech SA is a European company headquartered in Switzerland that specializes in the development and manufacturing of medical devices. The company was founded in 1999 and has since had an impressive history.
The business model of Medcom Tech SA is based on the idea of developing medical devices that meet the needs of doctors and patients. The company works closely with medical professionals to find innovative solutions that can improve medical care and accelerate patient recovery. The goal of Medcom Tech SA is to offer high-quality, safe, and reliable products that can be used worldwide in medical practice.
Medcom Tech SA offers a wide range of products divided into various sectors. One of the main sectors of the company is gastroenterology, where endoscopic devices and accessories are manufactured and distributed. These devices are a crucial foundation for the diagnosis and treatment of gastrointestinal diseases. The endoscopes enable more precise interventions and are particularly in demand for minimally invasive procedures.
Another important sector of the company is cardiology. Medcom Tech SA manufactures defibrillators and implantable devices in this sector. These devices help save lives and provide patients with more security in their daily lives. In particular, implantable devices are an essential part of modern medicine and contribute to allowing patients to lead long and healthy lives.
In addition to the mentioned sectors, Medcom Tech also develops and produces devices for the diagnosis and treatment of respiratory diseases, neurology, gynecology, and urology. For example, in urology, a product called ProstateCare has been developed, which is an innovative method for treating benign prostatic hyperplasia (BPH), a benign enlargement of the prostate gland.
Medcom Tech SA receives support in these business sectors from a network of international distribution partners who help distribute the products worldwide.
In conclusion, Medcom Tech SA has undergone an impressive development and is one of the leading companies in the medical device industry. The company has earned an excellent reputation in the medical industry and is known for its innovative solutions and high-quality products. The continuous collaboration with medical professionals and the consistent development of new technologies and products make Medcom Tech an important partner in the medical care world. Medcom Tech is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Medcom Tech stock
Operating Cash Flow of Medcom Tech is -1.96 M EUR in 2026.
Access this data via the Eulerpool API
Cash Flow — Medcom Tech
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Medcom Tech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth